NCIt definition : A mixture of the two engineered monoclonal antibodies iparomlimab, which is an immunoglobulin
G4 (IgG4) monoclonal antibody directed against the human negative immunoregulatory
checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and tuvonralimab,
which is an IgG1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated
antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic
activities. Upon administration of iparomlimab/tuvonralimab, iparomlimab and tuvonralimab
target and bind to PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs),
respectively. This inhibits the PD-1- and CTLA4-mediated downregulation of T-cell
activation and proliferation. This restores immune function and activates a cytotoxic
T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4
are selectively expressed on TILs in the tumor microenvironment (TME) and negatively
regulate the activation and effector functions of T-cells. They play key roles in
the downregulation of the immune system and tumor evasion from host immunity. Dual
checkpoint blockade of PD-1 and CTLA4 enhances T-cell activation and proliferation
more than the blockade of either immune checkpoint receptor alone.;
Molecule name : PSB-205; PSB 205; QL 1706; QL-1706;
Semantic type(s)